Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 200,161,360
  • Shares Outstanding, K 5,967,840
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 1.01
  • Price/Sales 3.80
  • Price/Cash Flow 9.94
  • Price/Book 3.41

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.99 +1.49%
on 07/13/17
34.48 -2.90%
on 06/22/17
-0.40 (-1.18%)
since 06/21/17
3-Month
31.67 +5.72%
on 06/08/17
34.48 -2.90%
on 06/22/17
-0.16 (-0.48%)
since 04/21/17
52-Week
29.83 +12.24%
on 11/03/16
37.39 -10.46%
on 08/01/16
-3.23 (-8.80%)
since 07/21/16

Most Recent Stories

More News
Merck's Biosimilar Insulin Gets Tentative FDA Approval

Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

MRK : 62.63 (-0.49%)
LLY : 84.66 (-0.11%)
PFE : 33.48 (-0.18%)
SNY : 47.71 (-0.73%)
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

NVO : 42.95 (-1.38%)
JNJ : 135.31 (-0.92%)
ABBV : 74.63 (+0.84%)
PFE : 33.48 (-0.18%)
HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?

HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.

CELG : 137.74 (+1.05%)
HCA : 85.73 (-0.03%)
GILD : 73.76 (+0.46%)
PFE : 33.48 (-0.18%)
Can Merck (MRK) Pull Off a Surprise this Earnings Season?

Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition....

NVO : 42.95 (-1.38%)
MRK : 62.63 (-0.49%)
VRTX : 163.17 (+2.41%)
PFE : 33.48 (-0.18%)
Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging

GLW : 31.85 (+0.44%)
MRK : 62.63 (-0.49%)
PFE : 33.48 (-0.18%)
What Lies in Store for Glaxo (GSK) this Earnings Season?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

MYL : 39.17 (-0.81%)
NVO : 42.95 (-1.38%)
PFE : 33.48 (-0.18%)
GSK : 42.66 (-0.26%)
Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole), A Novel Treatment For Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

Pfizer Inc. (NYSE:PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and oncological...

PFE : 33.48 (-0.18%)
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba(R) for Europe, Russia, Turkey and Israel

Basilea Pharmaceutica AG / Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba(R) for Europe, Russia, Turkey and Israel . Processed and transmitted by Nasdaq Corporate...

PFE : 33.48 (-0.18%)
4 Healthcare Megatrends for Investors

4 Healthcare Megatrends for Investors

ISRG : 927.47 (-4.55%)
PFE : 33.48 (-0.18%)
4 Healthcare Megatrends for Investors

4 Healthcare Megatrends for Investors

ISRG : 927.47 (-4.55%)
PFE : 33.48 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 33.67
1st Resistance Point 33.58
Last Price 33.48
1st Support Level 33.39
2nd Support Level 33.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.